Candel Therapeutics, Inc. (CADL)
$9.27-5.21%Close
SELLCRISIS · day 11
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $679M
- Beta
- -0.47
- P/E (TTM)
- -6.43
- Short % float
- 27.40%
- Days to cover
- 11.2
- SI change
- +5.3%
- 1W
- -6.08%
- 1M
- -13.20%
- vs SPY 1W
- -5.94%
- vs SPY 1M
- -15.71%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 7
- GROWTH
- 43
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-53.6%
REV YoY-
ROE-89.4%
EPS YoY-
ROA-42.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-6.43
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B5.33
P/FCF-
EV/EBITDA-6.16
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E39.26
ALTMAN Z-
CURR RATIO16.09
ND/EBITDA-
BETA-0.47
Company news
FAQ
- What is LOPJLB’s current signal on CADL?
- LOPJLB’s latest quantitative signal on Candel Therapeutics, Inc. (CADL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CADL in?
- Candel Therapeutics, Inc. (CADL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Candel Therapeutics, Inc. (CADL) do?
- Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trial…